Artiva Biotherapeutics
The incumbent will lead the strategic direction and scientific oversight of the cell potency analytical development group, developing and optimizing cell‑based assays for NK cell therapies. This role involves mentoring scientists, designing assay qualification and validation studies, and collaborating with R&D, process development, and QC teams to support product release and regulatory submissions.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2019
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases. Their lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) across multiple clinical trials, including basket trials in rheumatoid arthritis and Sjögren's disease. The company leverages highly scaled, off-the-shelf, allogeneic NK cell manufacturing to make cell therapies broadly accessible to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Artiva Biotherapeutics.
15% below the average for this role
Scientist I, Analytical Development
ImmunityBio
Scientist, Analytical Cell Line Engineering & Bioassay Development
BioLife Plasma Services
Senior Scientist I, Analytical Development, Biologics CMC
Exelixis
Senior/Principal Scientist, Analytical Cell Line Engineering and Bioassay Development
Takeda Pharmaceutical Company Limited
Associate Principal Scientist – Bioassay, Cell Based Sciences, AR&D
MSD
Senior/Principal Scientist, Cell Based-Potency Assay Development
BioLife Plasma Services